Objective    To investigate the correlation factors associated with the therapeutic efficacy of adefovir dipivoxil for patients with chronic hepatitis B.      Methods    Totally 34 hepatitis B patients with positive HBeAg were enrolled and treated with adefovir dipivoxil (10 mg once daily) for 132 weeks

and the biochemical and virological parameters were monitored. Statistic analysis was used to identify some possible correlation factors associated with therapeutic efficacy.     Results    Patients who achieved undetectable HBV DNA at the end of the treatment were found to have a lower baseline HBV DNA level

higher ALT and higher ratio of initial virologic response (IVR) compared with those who did not achieve (P=0.034

0.011

＜0.001); HBeAg seroconversion were observed more often in patients with lower baseline HBV DNA and those achieving IVR (P=0.034

＜0.001); And lower baseline HBV DNA and higher ALT predicted a higher probability for winning IVR (P=0.006

0.003). Linear regression identified negative correlations between body weight and the reduction level of HBV DNA at the week of 52

104 and 132 respectively (P=0.026

0.016

0.035).      Conclusion    Patients with lower baseline HBV DNA level

higher ALT and lower body weight were more prone to achieve virologic response. Thus

a higher dosage of adefovir dipivoxil is recommended for the patients with higher body weight.